PRKCA and central nervous system cancer: Regarding thymol, treatment at concentrations of 100 and 200 μM induced a significant reduction in cell viability and inhibited the migration of glioma cells (C6 cell line) through phosphorylation of PKCα and ERK1/2, that resulted in decreased expression of MMP-9 and MMP-2 (Lee et al., 2016).